Methylprednisolone detailed information

Methylprednisolone detailed information

Error creating thumbnail: File missing
Clinical data
Pregnancy category	C
Routes of administration	IV, IM, IV Infusion, oral
ATC code	D07AA01 (WHO) D07AC14 (WHO), D10AA02 (WHO), H02AB04 (WHO)
Pharmacokinetic data
Protein binding	78%
Metabolism	liver primarily, kidney, tissues; CYP450: 3A4 substrate
Elimination half-life	urine; Half-life: 18-26h (biological)
Identifiers
IUPAC name (6α, 11β)-11,17,21-trihydroxy-6-methyl-pregna-1,4-diene-3,20 -dione
CAS Number	83-43-2
PubChem CID	6741
DrugBank	APRD00342
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H30O5
Molar mass	374.471 g/mol

WikiDoc Resources for Methylprednisolone detailed information
Articles
Most recent articles on Methylprednisolone detailed information Most cited articles on Methylprednisolone detailed information Review articles on Methylprednisolone detailed information Articles on Methylprednisolone detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Methylprednisolone detailed information Images of Methylprednisolone detailed information Photos of Methylprednisolone detailed information Podcasts & MP3s on Methylprednisolone detailed information Videos on Methylprednisolone detailed information
Evidence Based Medicine
Cochrane Collaboration on Methylprednisolone detailed information Bandolier on Methylprednisolone detailed information TRIP on Methylprednisolone detailed information
Clinical Trials
Ongoing Trials on Methylprednisolone detailed information at Clinical Trials.gov Trial results on Methylprednisolone detailed information Clinical Trials on Methylprednisolone detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Methylprednisolone detailed information NICE Guidance on Methylprednisolone detailed information NHS PRODIGY Guidance FDA on Methylprednisolone detailed information CDC on Methylprednisolone detailed information
Books
Books on Methylprednisolone detailed information
News
Methylprednisolone detailed information in the news Be alerted to news on Methylprednisolone detailed information News trends on Methylprednisolone detailed information
Commentary
Blogs on Methylprednisolone detailed information
Definitions
Definitions of Methylprednisolone detailed information
Patient Resources / Community
Patient resources on Methylprednisolone detailed information Discussion groups on Methylprednisolone detailed information Patient Handouts on Methylprednisolone detailed information Directions to Hospitals Treating Methylprednisolone detailed information Risk calculators and risk factors for Methylprednisolone detailed information
Healthcare Provider Resources
Symptoms of Methylprednisolone detailed information Causes & Risk Factors for Methylprednisolone detailed information Diagnostic studies for Methylprednisolone detailed information Treatment of Methylprednisolone detailed information
Continuing Medical Education (CME)
CME Programs on Methylprednisolone detailed information
International
Methylprednisolone detailed information en Espanol Methylprednisolone detailed information en Francais
Business
Methylprednisolone detailed information in the Marketplace Patents on Methylprednisolone detailed information
Experimental / Informatics
List of terms related to Methylprednisolone detailed information

Methylprednisolone (molecular weight 374.48) is a synthetic glucocorticoid drug taken orally or administered intraveinously. Its chemical name is pregna-1,4-diene-3,20 -dione, 11,17,21-trihydroxy-6-methyl-,(6α, 11β)- and its chemical formula is C₂₂H₃₀O₅. Methylprednisolone is sold in the USA and Canada under the brand name Medrol.

Like most adrenocortical steroids, methylprednisolone is typically used for its anti-inflammatory purposes. However, glucocorticoids have a wide range of effects, including changes to metabolism and immune responses. The list of medical conditions for which methlyprednisolone is prescribed is rather large, and is similar to other corticosteroids such as prednisolone. Common uses include arthritis therapy and short-term treatment of bronchial inflammation or acute bronchitis due to various respiratory diseases. It is used both in the treatment of acute periods and long-term controlling of autoimmune diseases, most notably SLE.

Methylprednisolone has serious side effects if taken long-term, including weight gain, glaucoma, osteoporosis and psychosis, especially when overdosed. The most serious side effect occurs after the adrenal glands cease natural production of cortisone, which methylprednisolone will replace. Abrupt cessation of the drug after this occurs can result in a condition known as Addisonian crisis, which can be fatal. To prevent this, the drug is usually prescribed with a tapering dosage, including a pre-dosed "dose pack" detailing a specific number of pills to take at designated times over a six day period.

Alternative treatments to many of the conditions currently indicated for methlyprednisolone are actively being researched. Additionally, new drugs such as budesonide are being created, which provide similar benefits but without the adrenal suppression problems.